Emerging Therapies and Changing Architecture of HIV Management
Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study.
Aboud M, et al. 9th International AIDS Society Conference. July 23-26, 2017; Paris, France. Abstract TUAB0105LB.
Removing the stigma of HIV.
American Pharmacists Association, 2017.
Effect of HIV antibody VRC01 on viral rebound after treatment interruption.
Bar KJ, et al. N Engl J Med. 2016;375(21):2037-2050.
Frequency of HIV testing and time from infection to diagnosis improve.
Centers for Disease Control and Prevention, 2017.
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1–infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L, et al. Lancet HIV. 2017;4(9):e384-e392.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, et al. Lancet. 2017;390(10107):2063-2072.
Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials.
Hill AM, et al. Curr Opin HIV AIDS. 2018;13(2):102-111.
Initiation of antiretroviral therapy in early asymptomatic HIV infection.
The INSIGHT START Study Group. N Engl J Med. 2015;373(9):795-807.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM, et al. Lancet. 2018;391(10123):839-849.
Phase 3 study of fostemsavir in heavily treatment-experienced HIV-1–infected participants: day 8 and week 24 primary efficacy and safety results (BRIGHTE Study, formerly 205888/AI438-047).
Kozal M, et al. 16th European AIDS Conference. October 25-27, 2017; Milan, Italy. Abstract PS8/5.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA, et al. Lancet. 2017;390(10101):1499-1510.
Resistance against integrase strand transfer inhibitors and relevance to HIV persistence.
Mesplède T, Wainberg MA. Viruses. 2015;7(7):3703-3718.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM, et al. Lancet HIV. 2018;5(5):e211-e220.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C, et al. Lancet HIV. 2018;5(1):e23-e34.
The role of substance use and mental health problems in medication adherence among HIV-infected MSM.
White JM, et al. LGBT Health. 2014;1(4):319-322.
Pooled week 48 efficacy and baseline resistance: B/F/TAF in treatment-naïve patients.
White K, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI), 2018. March 4−7, 2018; Boston, MA. Abstract 532.
Clinical Practice Guidelines
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV.
US Department of Health and Human Services, 2018.
Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations.
Centers for Disease Control and Prevention, 2018.
Updated PrEP Clinical Practice Guideline and PrEP Clinical Providers’ Supplement—2017.
Centers for Disease Control and Prevention, 2017.
Clinical Resources
American Academy of HIV Medicine | Supporting the HIV Care Provider and the Profession.
Database of Antiretroviral Drug Interactions.
HIV Insite. University of California, San Francisco.
HIV Drug Interactions.
University of Liverpool (Web site), 2018.
PrEP Kit.
AIDS United, 2015.
Patient Resources
HIV Risk Reduction Tool.
Centers for Disease Control and Prevention, 2017.
Centers for Disease Control and Prevention (CDC): HIV Basics.
The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This comprehensive site provides extensive links to topics across the HIV-care continuum, including preexposure prophylaxis (PrEP).
Pill-Reminder Smartphone Apps (Free).
Mango Health – Medicine Manager, Pill Reminder for iPhone.
Medisafe Pill Reminder, Rx, & Medicine Tracker for iPhone.
Medisafe Meds & Pill Reminder for Android.
Positively Aware.
Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for men who have sex with men and transgender people.
PrEP for U.S. Women: A Collection of Resources.
HIVE (Website).
HIVE provides preconception and prenatal care and resources for women and couples affected by HIV.
Evaluations And Treatment of Virologic Failure
Emerging Concepts
| Faculty: | Paul E. Sax, MD; Timothy J. Wilkin MD, MPH |
| Release: | 07/23/2018 |
| Expiration: | 07/23/2019 |
The Changing Architecture of HIV Care
Review of Novel Agents and Approaches
| Faculty: | Paul E. Sax, MD; Timothy J. Wilkin MD, MPH |
| Release: | 08/10/2018 |
| Expiration: | 08/10/2019 |
